BioCentury
ARTICLE | Clinical News

Zynerba refocusing on CBD gel following failed patch readout

July 13, 2018 6:55 PM UTC

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will focus on developing ZYN002 after single and multiple doses of several formulations of ZYN001 failed to achieve target blood levels of 5-15 ng/mL of tetrahydrocannabinol (THC) in a Phase I trial in 60 healthy volunteers. The company had planned to start a Phase II trial this year of ZYN001 to treat Tourette’s syndrome.

The company, which had $52.1 million in cash at March 31, said it expects the shift in focus to extend its runway to 2H19...

BCIQ Company Profiles

Zynerba Pharmaceuticals Inc.

BCIQ Target Profiles

Cannabinoid receptors